Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in clinical development stage for the treatment of hereditary angioedema. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is based in Boston, Massachusetts.
Astria Therapeutics, Inc. Frequently Asked Questions
What is the ticker symbol for Astria Therapeutics, Inc.? What does ATXS stand for in stocks?
ATXS is the stock ticker symbol of Astria Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Astria Therapeutics, Inc. (ATXS)?
As of Wed Dec 04 2024, market cap of Astria Therapeutics, Inc. is 572.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of ATXS stock?
You can check ATXS's fair value in chart for subscribers.
Is Astria Therapeutics, Inc. a good stock to buy?
The fair value guage provides a quick view whether ATXS is over valued or under valued. Whether Astria Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Astria Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ATXS.